FDA approves belzutifan with lenvatinib for advanced kidney cancer after immunotherapy. It delayed tumor growth, but the survival gain was not significant.
Kidney Cancer Patients Gain New Two-Pill Option as FDA Approves Belzutifan Combo Without Proven Survival Benefit
by | Sep 25, 2026 | Uncategorized | 0 comments
Recent Comments